by Peter Ciszewski | May 28, 2020
The U.S. Food and Drug Administration (FDA) has approved intravenous (IV) artesunate to treat patients with severe malaria. The treatment should always be followed by a complete treatment course of an appropriate oral antimalarial regimen. Until now, IV artesunate...
by Peter Ciszewski | May 27, 2020
Dror Bashan, President and CEO of Protalix Biotherapeutics talks about the company’s Fabry disease pipeline, that includes pegunigalsidase alfa, a plant based enzyme replacement therapy, that is currently under investigation in numerous clinical trials to...
by Peter Ciszewski | May 26, 2020
Courtney DiNardo, MD, Associate Professor at the University of Texas MD Anderson Cancer Center, explains how treatment strategies have changed for managing elderly patients with acute myeloid leukemia (AML). AML is a rare blood cancer that tends to occur more...
by Peter Ciszewski | May 25, 2020
The U.S. Food and Drug Administration (FDA) has approved Alunbrig (brigatinib) as first-line therapy to treat adults with a rare form of lung cancer—anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). Approximately 3-5% of...
by Peter Ciszewski | May 22, 2020
Ronald Hoffman, MD, Director of the Myeloproliferative Diseases Program at The Icahn School of Medicine at Mount Sinai, describes the findings of an ongoing Phase II clinical trial assessing the safety and efficacy PTG-300 to treat individuals with polycythemia...
